CN106619696A - Compound blood glucose lowering preparation - Google Patents
Compound blood glucose lowering preparation Download PDFInfo
- Publication number
- CN106619696A CN106619696A CN201611011439.XA CN201611011439A CN106619696A CN 106619696 A CN106619696 A CN 106619696A CN 201611011439 A CN201611011439 A CN 201611011439A CN 106619696 A CN106619696 A CN 106619696A
- Authority
- CN
- China
- Prior art keywords
- parts
- metformin
- compound preparation
- hypoglycemic compound
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- 239000008280 blood Substances 0.000 title abstract description 18
- 210000004369 blood Anatomy 0.000 title abstract description 18
- 150000001875 compounds Chemical class 0.000 title abstract description 5
- 230000010030 glucose lowering effect Effects 0.000 title abstract 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 36
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229960003105 metformin Drugs 0.000 claims abstract description 28
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims abstract description 19
- 108010061435 Enalapril Proteins 0.000 claims abstract description 19
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 19
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims abstract description 19
- 229960000873 enalapril Drugs 0.000 claims abstract description 19
- 150000004676 glycans Chemical class 0.000 claims abstract description 19
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 19
- 239000005017 polysaccharide Substances 0.000 claims abstract description 19
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 19
- 229960002675 xylitol Drugs 0.000 claims abstract description 19
- 235000010447 xylitol Nutrition 0.000 claims abstract description 19
- 239000000811 xylitol Substances 0.000 claims abstract description 19
- 241000206609 Porphyra Species 0.000 claims abstract description 18
- 229940109262 curcumin Drugs 0.000 claims abstract description 18
- 235000012754 curcumin Nutrition 0.000 claims abstract description 18
- 239000004148 curcumin Substances 0.000 claims abstract description 18
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 18
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960001381 glipizide Drugs 0.000 claims abstract description 17
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000003472 antidiabetic agent Substances 0.000 claims description 33
- 239000002994 raw material Substances 0.000 claims description 11
- 230000008020 evaporation Effects 0.000 claims description 9
- 238000001704 evaporation Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 8
- -1 garlicin Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000012467 final product Substances 0.000 claims description 7
- 229960000956 coumarin Drugs 0.000 claims description 4
- 235000001671 coumarin Nutrition 0.000 claims description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 229960004198 guanidine Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 abstract description 2
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 abstract description 2
- 235000010081 allicin Nutrition 0.000 abstract description 2
- 235000000346 sugar Nutrition 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 229930182827 D-tryptophan Natural products 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 23
- 239000008103 glucose Substances 0.000 description 23
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 235000001727 glucose Nutrition 0.000 description 10
- 229940123208 Biguanide Drugs 0.000 description 9
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 239000003814 drug Substances 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- VBVAVBCYMYWNOU-UHFFFAOYSA-N coumarin 6 Chemical group C1=CC=C2SC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 VBVAVBCYMYWNOU-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a compound blood glucose lowering preparation. The compound blood glucose lowering preparation is mainly prepared from, by weight, 12-17 parts of metformin, 5-9 parts of D-tryptophan, 8-15 parts of enalapril, 3-6 parts of coumarin, 8-14 parts of porphyra polysaccharide, 5-7 parts of allicin, 4-12 parts of xylitol, 15-30 parts of metformin, 4-9 parts of glipizide and 10-15 parts of curcumin. The compound blood glucose lowering preparation has the advantages of being capable of effectively reducing blood sugar, quick to take effect, good in treating effect and free of toxic and side effects.
Description
Technical field
The present invention relates to a kind of pharmaceutical technology field, specifically a kind of hypoglycemic compound preparation.
Background technology
Diabetes are a kind of incretion metabolism diseases, are because internal insulin is relative or saccharide that is definitely not enough and causing
Metabolism disorder, the disease for causing sugar, protein, fatty and secondary water and electrolyte metabolism disorderly.Diabetes are clinically divided to two
Type：Insulin dependent diabetes mellitus (IDDM) (i.e. type i diabetes), non-insulin-dependent diabetes mellitus (i.e. type ii diabetes).Its
In, type ii diabetes rate is very high, accounts for 90% or so of onset diabetes number.The harm of diabetes essentially from complication,
Its incidence rate is very high, result in high fatality rate and high disability rate.Research shows there is 30%～40% in 10 years after onset diabetes
There is a kind of complication to I haven't seen you for ages in patient.Common diabetic complication has nephropathy, eyes pathological changes, the god that diabetes cause
Jing system pathological changes, cardiovascular pathological changes, fatty liver etc..
World Health Organization (WHO) announces recently, nineteen ninety-five whole world diabeticss only 30,000,000 people or so, and by 1997 years
Oneself increases to 1.35 hundred million, predicts according to authoritative sources, and by 2010 2.4 hundred million were up to, and by 2025, will have 3.3 hundred million people to be diagnosed as
Diabetes, and mortality rate is only second to malignant tumor and cardiovascular diseasess, is the third-largest disease for jeopardizing human life and health.With
The raising of living standards of the people, the incidence rate and mortality rate of China's diabeticss are also increasing severely year by year.Distinguish from China various places
From the point of view of the finding of cloth, the eighties China's diabeticss sickness rate less than 1%, had risen to 2.65% by 1997,
And more increased rapidly with annual 0.1% speed in recent years, the diseased colonies that can not be ignored have been formed.At present, China
The diabetes outbreak period is had been enter into, patient 3000 is at least increased daily.The treatment and prevention of diabetes and its complication are compeled in eyebrow
Eyelash.
Although on the market oral antidiabetic drug species is various, so far, can also be with one's own without which kind of medicine
The HbAlc levels of type ii diabetes patient are maintained at for a long time within target zone.As can be seen here, exploitation has brand-new effect machine
The new antidiabetic drug of system and preferably risk/benefit ratio has become a urgently to be resolved hurrily vital task.
The content of the invention
It is an object of the invention to provide a kind of hypoglycemic compound preparation, to solve above-mentioned background technology in propose ask
Topic.
For achieving the above object, the present invention provides following technical scheme：
A kind of hypoglycemic compound preparation, be according to the primary raw material of weight portion：Metformin 12-17 parts, D-trp
5-9 parts, Enalapril 8-15 parts, coumarin 3-6 parts, Porphyra Polysaccharide 8-14 parts, garlicin 5-7 parts, xylitol 4-12 parts, two
First biguanide 15-30 part, Glipizide 4-9 part, curcumin 10-15 parts.
As further scheme of the invention：The hypoglycemic compound preparation, be according to the primary raw material of weight portion：Two
It is first biguanide 14-16 part, D-trp 5-9 parts, Enalapril 11-14 parts, coumarin 3-6 parts, Porphyra Polysaccharide 10-13 parts, big
Allicin 5-7 parts, xylitol 7-11 parts, metformin 19-25 parts, Glipizide 4-9 part, curcumin 11-14 parts.
As further scheme of the invention：The hypoglycemic compound preparation, be according to the primary raw material of weight portion：Two
15 parts of first biguanide, 8 parts of D-trp, 12 parts of Enalapril, 5 parts of coumarin, 11 parts of Porphyra Polysaccharide, 6 parts of garlicin, xylitol
9 parts, 22 parts of metformin, 7 parts of Glipizide, 13 parts of curcumin.
A kind of preparation method of hypoglycemic compound preparation, concretely comprises the following steps：
First, by metformin, D-trp, Enalapril, coumarin, Porphyra Polysaccharide, garlicin, xylitol, two
First biguanide, Glipizide, curcumin are mixed, and constantly add water stirring, and mixing speed is controlled in 100-150r/min, and stirring terminates
Afterwards, the evaporation and concentration at 60-80 DEG C, sieves after being dried, and pack obtains final product hypoglycemic compound preparation.
As further scheme of the invention：Mixing speed is controlled in 130r/min in concrete steps.
As further scheme of the invention：In concrete steps at 70 DEG C evaporation and concentration.
Compared with prior art, the invention has the beneficial effects as follows：
The present invention can effectively reduce blood glucose, with instant effect, good effect and the characteristics of have no toxic side effect, also with guarantor
The function of shield heart blood vessel increase coronary blood flow, blood fat reducing and enhancing human body immunity power.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than the embodiment of whole.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of hypoglycemic compound preparation, be according to the primary raw material of weight portion：12 parts of metformin, 5 parts of D-trp,
8 parts of Enalapril, 3 parts of coumarin, 8 parts of Porphyra Polysaccharide, 5 parts of garlicin, 4 parts of xylitol, 15 parts of metformin, Glipizide
4 parts, 10 parts of curcumin.
A kind of preparation method of hypoglycemic compound preparation, concretely comprises the following steps：
First, by metformin, D-trp, Enalapril, coumarin, Porphyra Polysaccharide, garlicin, xylitol, two
First biguanide, Glipizide, curcumin are mixed, and constantly add water stirring, and mixing speed control is stirred after terminating in 100r/min, in
Evaporation and concentration at 60 DEG C, sieves after being dried, and pack obtains final product hypoglycemic compound preparation.
Embodiment 2
A kind of hypoglycemic compound preparation, be according to the primary raw material of weight portion：14 parts of metformin, 5 parts of D-trp,
11 parts of Enalapril, 3 parts of coumarin, 10 parts of Porphyra Polysaccharide, 5 parts of garlicin, 7 parts of xylitol, 19 parts of metformin, lattice row pyrrole
4 parts of piperazine, 11 parts of curcumin.
A kind of preparation method of hypoglycemic compound preparation, concretely comprises the following steps：
First, by metformin, D-trp, Enalapril, coumarin, Porphyra Polysaccharide, garlicin, xylitol, two
First biguanide, Glipizide, curcumin are mixed, and constantly add water stirring, and mixing speed control is stirred after terminating in 115r/min, in
Evaporation and concentration at 65 DEG C, sieves after being dried, and pack obtains final product hypoglycemic compound preparation.
Embodiment 3
A kind of hypoglycemic compound preparation, be according to the primary raw material of weight portion：15 parts of metformin, 8 parts of D-trp,
12 parts of Enalapril, 5 parts of coumarin, 11 parts of Porphyra Polysaccharide, 6 parts of garlicin, 9 parts of xylitol, 22 parts of metformin, lattice row pyrrole
7 parts of piperazine, 13 parts of curcumin.
A kind of preparation method of hypoglycemic compound preparation, concretely comprises the following steps：
First, by metformin, D-trp, Enalapril, coumarin, Porphyra Polysaccharide, garlicin, xylitol, two
First biguanide, Glipizide, curcumin are mixed, and constantly add water stirring, and mixing speed control is stirred after terminating in 130r/min, in
Evaporation and concentration at 70 DEG C, sieves after being dried, and pack obtains final product hypoglycemic compound preparation.
Embodiment 4
A kind of hypoglycemic compound preparation, be according to the primary raw material of weight portion：16 parts of metformin, 9 parts of D-trp,
14 parts of Enalapril, coumarin 6 part, 13 parts of Porphyra Polysaccharide, 7 parts of garlicin, 11 parts of xylitol, 25 parts of metformin, lattice row
9 parts of pyrazine, 14 parts of curcumin.
A kind of preparation method of hypoglycemic compound preparation, concretely comprises the following steps：
First, by metformin, D-trp, Enalapril, coumarin, Porphyra Polysaccharide, garlicin, xylitol, two
First biguanide, Glipizide, curcumin are mixed, and constantly add water stirring, and mixing speed control is stirred after terminating in 140r/min, in
Evaporation and concentration at 77 DEG C, sieves after being dried, and pack obtains final product hypoglycemic compound preparation.
Embodiment 5
A kind of hypoglycemic compound preparation, be according to the primary raw material of weight portion：17 parts of metformin, 9 parts of D-trp,
15 parts of Enalapril, coumarin 6 part, 14 parts of Porphyra Polysaccharide, 7 parts of garlicin, 12 parts of xylitol, 30 parts of metformin, lattice row
9 parts of pyrazine, 15 parts of curcumin.
A kind of preparation method of hypoglycemic compound preparation, concretely comprises the following steps：
First, by metformin, D-trp, Enalapril, coumarin, Porphyra Polysaccharide, garlicin, xylitol, two
First biguanide, Glipizide, curcumin are mixed, and constantly add water stirring, and mixing speed control is stirred after terminating in 150r/min, in
Evaporation and concentration at 80 DEG C, sieves after being dried, and pack obtains final product hypoglycemic compound preparation.
Clinical verification：
Using method：Type ii diabetes patient totally 100, wherein man 58, female 42, patient age 30～60 years old, one
Days three times, before meals half an hour take the compound preparation of the preparation of the embodiment of the present invention 3, each 500mg 7 days is a course for the treatment of.On an empty stomach
Blood glucose (FPG) and 2h-plasma glucose (2hPG) are significantly raised.Take two courses for the treatment of of medicine of the preparation of the embodiment of the present invention 1
Afterwards, above-mentioned biochemical indicator is detected.Cure：FPG ＜ 6.1mmol/L, 2h blood glucose (2hPG) ＜ 8.0mmol/L.Effectively：Fasting glucose
(FPG), 2h-plasma glucose (2hPG) makes moderate progress, but not up to normal level.It is invalid：Fasting glucose (FPG), 2h-plasma glucose
(2hPG) without substantially change.
Therapeutic effect：Cure 98, effective 1, invalid 1, total effective rate is more than 99%.
Model case：
Wang, man, 34 years old, fasting glucose 7.4mmol/L, after the meal two hours blood glucose 10.5mmol/L, takes medicine of the present invention
After one course for the treatment of of thing, fasting glucose is down to 5.8mmol/L, and after the meal two hours blood glucoses are down to 7.1mmol/L, continues to take a treatment
Withdrawal after journey, without rebound phenomena.
Sun, female 47 years old, suffers from for many years diabetes, Glipizide is taken always and is not cured, and Jing often recurs, fasting glucose
8.9mmol/L, after the meal two hours blood glucose 10.5mmol/L, after taking two courses for the treatment of of medicine of the present invention, fasting glucose is down to
5.2mmol/L, after the meal two hours blood glucose 8.4mmol/L, gradually subtracts the half of dose, then takes fasting glucose after a course for the treatment of and stablize
In 4.7mmol/L, two hours after meal is 6.5mmol/L, and Follow-up observation half a year blood glucose does not rebound.
Zhang, man, 58 years old, suffers from for many years diabetes, Glipizide, Acarbose is taken always and is not cured, and Jing often recurs, on an empty stomach
Blood glucose 9.5mmol/L, after the meal two hours blood glucose 13.7mmol/L, after taking two courses for the treatment of of medicine of the present invention, fasting glucose is down to
6.3mmol/L, after the meal two hours blood glucose 10.2mmol/L, gradually subtract the half of dose, then to take fasting glucose after a course for the treatment of steady
5.8mmol/L is scheduled on, two hours after meal is 7.5mmol/L, and Follow-up observation half a year blood glucose does not rebound.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of description is only that for clarity those skilled in the art should
Using description as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art
Understandable other embodiment.
Claims (6)
1. a kind of hypoglycemic compound preparation, it is characterised in that the primary raw material according to weight portion is：Metformin 12-17 parts,
D-trp 5-9 parts, Enalapril 8-15 parts, coumarin 3-6 parts, Porphyra Polysaccharide 8-14 parts, garlicin 5-7 parts, xylitol
4-12 parts, metformin 15-30 parts, Glipizide 4-9 part, curcumin 10-15 parts.
2. hypoglycemic compound preparation according to claim 1, it is characterised in that the hypoglycemic compound preparation, presses
It is according to the primary raw material of weight portion：Metformin 14-16 parts, D-trp 5-9 parts, Enalapril 11-14 parts, coumarin 3-
6 parts, Porphyra Polysaccharide 10-13 parts, garlicin 5-7 parts, xylitol 7-11 parts, metformin 19-25 parts, Glipizide 4-9 part, Rhizoma Zingiberis Recens
Flavin 11-14 parts.
3. hypoglycemic compound preparation according to claim 1 and 2, it is characterised in that the hypoglycemic compound preparation,
Primary raw material according to weight portion is：15 parts of metformin, 8 parts of D-trp, 12 parts of Enalapril, 5 parts of coumarin, Thallus Porphyrae
11 parts of polysaccharide, 6 parts of garlicin, 9 parts of xylitol, 22 parts of metformin, 7 parts of Glipizide, 13 parts of curcumin.
4. a kind of preparation method of the hypoglycemic compound preparation as described in claim 1-3 is arbitrary, it is characterised in that concrete step
Suddenly it is：
First, it is metformin, D-trp, Enalapril, coumarin, Porphyra Polysaccharide, garlicin, xylitol, diformazan is double
Guanidine, Glipizide, curcumin are mixed, and constantly add water stirring, and mixing speed control is stirred after terminating in 100-150r/min, in
Evaporation and concentration at 60-80 DEG C, sieves after being dried, and pack obtains final product hypoglycemic compound preparation.
5. the preparation method of hypoglycemic compound preparation according to claim 4, it is characterised in that stir in concrete steps
Speed controlling is in 130r/min.
6. the preparation method of hypoglycemic compound preparation according to claim 4, it is characterised in that in 70 in concrete steps
Evaporation and concentration at DEG C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611011439.XA CN106619696A (en) | 2016-11-17 | 2016-11-17 | Compound blood glucose lowering preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611011439.XA CN106619696A (en) | 2016-11-17 | 2016-11-17 | Compound blood glucose lowering preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106619696A true CN106619696A (en) | 2017-05-10 |
Family
ID=58807937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611011439.XA Pending CN106619696A (en) | 2016-11-17 | 2016-11-17 | Compound blood glucose lowering preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106619696A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1070827A (en) * | 1992-10-26 | 1993-04-14 | 济南市中心医院 | Up-to-date therapeutic agent of diabetes and method for making thereof |
| CN102060824A (en) * | 2009-11-13 | 2011-05-18 | 天津金世制药有限公司 | Method for preparing coumarin |
| CN102458360A (en) * | 2009-05-01 | 2012-05-16 | 阿普塔利斯医药科技公司 | Orally disintegrating tablet composition containing combination of high dose and low dose drug |
| CN103230422A (en) * | 2013-04-10 | 2013-08-07 | 广东工业大学 | A curcumin healthy granule and a preparation method thereof |
| CN104357509A (en) * | 2014-10-22 | 2015-02-18 | 哈尔滨艾博雅食品科技开发有限公司 | Extraction method of seaweed crude polysaccharide |
| CN104415027A (en) * | 2013-08-30 | 2015-03-18 | 深圳华大基因科技有限公司 | The use of allicin in regulating the intestinal flora of animals |
-
2016
- 2016-11-17 CN CN201611011439.XA patent/CN106619696A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1070827A (en) * | 1992-10-26 | 1993-04-14 | 济南市中心医院 | Up-to-date therapeutic agent of diabetes and method for making thereof |
| CN102458360A (en) * | 2009-05-01 | 2012-05-16 | 阿普塔利斯医药科技公司 | Orally disintegrating tablet composition containing combination of high dose and low dose drug |
| CN102060824A (en) * | 2009-11-13 | 2011-05-18 | 天津金世制药有限公司 | Method for preparing coumarin |
| CN103230422A (en) * | 2013-04-10 | 2013-08-07 | 广东工业大学 | A curcumin healthy granule and a preparation method thereof |
| CN104415027A (en) * | 2013-08-30 | 2015-03-18 | 深圳华大基因科技有限公司 | The use of allicin in regulating the intestinal flora of animals |
| CN104357509A (en) * | 2014-10-22 | 2015-02-18 | 哈尔滨艾博雅食品科技开发有限公司 | Extraction method of seaweed crude polysaccharide |
Non-Patent Citations (1)
| Title |
|---|
| 肖林 等: "马来酸依那普利叶酸片对糖尿病合并H 型高血压患者血糖的影响", 《广东医学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102511712A (en) | Xylo-oligosaccharide-containing healthcare food auxiliary for blood sugar reduction | |
| CN104257696B (en) | A kind of steady sugar yeast bacterium powder of hypoglycemic and its preparation method and application | |
| CN103599137B (en) | One kind of multiple micronutrient element health product | |
| CN104873546A (en) | Novel propolis soft capsule and preparation method thereof | |
| CN106581301A (en) | Compound preparation for reducing blood glucose | |
| CN106619696A (en) | Compound blood glucose lowering preparation | |
| CN103550281A (en) | Medicine composition for preventing and treating diabetes and diabetes complications and preparation thereof | |
| CN103704428A (en) | Ginkgo health tea and preparation method thereof | |
| TW202034790A (en) | Bitter gourd peptide composition | |
| CN106110310A (en) | A kind of compound for reducing blood suger containing pioglitazone and preparation method thereof | |
| CN107048391A (en) | A kind of auxiliary hyperglycemic electuary and preparation method thereof | |
| CN103055176A (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN102058098A (en) | Health food with efficacy of lowering blood sugar and preparation method thereof | |
| CN102366098A (en) | Supercritical propolis soft capsules and preparation method thereof | |
| CN104621574A (en) | Formula food suitable for diabetic patients and preparation method thereof | |
| CN102266528B (en) | Medicament for treating hypertension | |
| CN102293817B (en) | Traditional Chinese medicine composition for reducing blood sugar and preparation method thereof | |
| CN109758429A (en) | A kind of Gliclazide sustained-release tablet and preparation method thereof | |
| CN103893302B (en) | A kind of hypertension and hyperlipemia Chinese medicine composition and its preparation method | |
| CN101347511A (en) | Medicament composition with function for reducing blood sugar | |
| CN108079275A (en) | A kind of health Chinese medicine composition for treating hypertension and preparation method thereof | |
| CN107137621A (en) | It is a kind of to treat Chinese medicine composition of high fat of blood and its preparation method and application | |
| CN115669935A (en) | Preparation for nourishing pancreas islet, reducing blood sugar, regulating blood pressure and blood fat and its preparation method | |
| Wasana et al. | A novel herbal capsule for the management of type 2 diabetes mellitus | |
| CN107156846A (en) | Complex health care product that is a kind of antifatigue and improving anoxia endurance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |
|
| RJ01 | Rejection of invention patent application after publication |